Contribute Try STAT+ Today

A stealth-mode startup backed by one of Boston’s biggest venture capital firms, Flagship Pioneering, is planning to graduate from shared lab space to a much larger leased lab in Kendall Square, and is expecting to more than triple its staff by 2020, according to new details made public for the first time Thursday.

The company — still referred to by its stealth-mode moniker “VL49” — is one of several new startups trying to leverage three buzzy technologies: artificial intelligence, CRISPR, and single-celled sequencing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.